These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1563 related items for PubMed ID: 16477566

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 24. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.
    J Infect Dis; 2009 Nov 15; 200(10):1490-7. PubMed ID: 19832114
    [Abstract] [Full Text] [Related]

  • 25. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P, de Górgolas M, Estrada V, Arranz A, Rivas P, Yera C, García R, Granizo JJ, Fernández-Guerrero M.
    Clin Infect Dis; 2004 Oct 01; 39(7):1024-9. PubMed ID: 15472856
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.
    Clin Infect Dis; 2005 Mar 01; 40(5):728-34. PubMed ID: 15714420
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.
    Clin Infect Dis; 2008 Jan 15; 46(2):305-12. PubMed ID: 18171267
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
    Resino S, M Bellón J, Gurbindo D, Tomás Ramos J, Antonio León J, Jose Mellado M, Angeles Muñoz-Fernández M.
    Clin Infect Dis; 2003 Nov 01; 37(9):1216-25. PubMed ID: 14557967
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.
    Pediatrics; 2005 Apr 01; 115(4):e488-94. PubMed ID: 15772172
    [Abstract] [Full Text] [Related]

  • 37. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.
    Sterling TR, Chaisson RE, Keruly J, Moore RD.
    J Infect Dis; 2003 Dec 01; 188(11):1659-65. PubMed ID: 14639536
    [Abstract] [Full Text] [Related]

  • 38. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA, Cheingsong R, Garcìa-Lerma JG, Eholié S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN.
    AIDS; 2003 Jul 01; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [Abstract] [Full Text] [Related]

  • 39. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence.
    Verweel G, Saavedra-Lozano J, van Rossum AM, Ramilo O, de Groot R.
    Pediatr Infect Dis J; 2006 Nov 01; 25(11):987-94. PubMed ID: 17072119
    [Abstract] [Full Text] [Related]

  • 40. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J.
    Clin Infect Dis; 2007 Oct 01; 45(7):925-32. PubMed ID: 17806063
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 79.